Foghorn Therapeutics Inc. - Common Stock (FHTX)

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development.

Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.